Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%(arstechnica.com)
136 points by _Microft | 25 comments
Ars Technica article reporting Phase 3 results showing Moderna and Merck's personalized mRNA melanoma vaccine with Keytruda cut recurrence or death risk by 42%.



